|

AK129(dose 1) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Akeso1

Indications

  • Non-small Cell Lung Cancer Stage IIIB/IV1
  • Colorectal Adenocarcinoma1
  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Advanced Solid Tumors1
  • Lung Cancer1

Other1 trial

AK129 Combination Therapy for Advanced Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.